Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of the Safety and Efficacy of 2% Pilocarpine Ophthalmic Spray Administered With the Optejet® Microdose Dispenser for Temporary Improvement of Near Vision in Adults With Presbyopia

NCT05114486 is registered in ClinicalTrials.gov with Eyenovia Inc. as lead sponsor.

NCT NCT05114486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05114486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of the Safety and Efficacy of 2% Pilocarpine Ophthalmic Spray Administered With the Optejet® Microdose Dispenser for Temporary Improvement of Near Vision in Adults With Presbyopia
Lead sponsor
Eyenovia Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 3, 2021
Completion date
September 20, 2022
Enrollment
145 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

presbyopia